DCAT Community 对比 PharmaCompass 的使用情况和统计数据

The DCAT Mobile App is the must-have resource for employees of DCAT Member Companies. Connect with other member representatives, get ready DCAT Week, and access member benefits and exclusive content right at your fingertips all year long!
  • Apple 应用商店
  • 免费
  • 商业

商店排名

- -

PharmaCompass’ Mobile App offers the easiest way for business to business (B2B) users to connect with partners to accelerate drug development activities using their mobile phones. Professionals can use the app to connect seamlessly with companies that can offer active pharmaceutical ingredients (API), finished dosage formulations (FDF), excipients and/or contract services to develop drug products. With over 1.5 million users, PharmaCompass is the leading platform for professionals to place orders with business partners to accelerate their drug development activities and also to gather market intelligence. FEATURES: Discover companies and products - Connect with the people in the companies that are in the best position to offer the right solutions - Find information on the relevant products (e.g. regulatory filings, price trends, patents etc.) and companies Stay up-to-date on business opportunities - Access / Post enquiries onto one of the largest on line pharmaceutical marketplaces - Find the latest news from top news sources - Enable notifications to receive updates on the topics of your interest Other Features: - With off-line access, users can easily read their favorite trends and opportunities - Share PharmaCompass' app, latest trends and opportunities with others Get the PharmaCompass mobile app – the right way to connect with the latest pharma & biotech business information at your fingertips.
  • Apple 应用商店
  • 免费
  • 商业

商店排名

- -

DCAT Community与PharmaCompass排名比较

对比 DCAT Community 与 PharmaCompass 在过去 28 天内的排名趋势

排名

没有可用的数据

DCAT Community 对比 PharmaCompass 的排名,按国家/地区比较

对比 DCAT Community 与 PharmaCompass 在过去 28 天内的排名趋势

无数据可显示

通过免费试用版比较任何网站

开始使用
DCAT Community VS.
PharmaCompass

一月 18, 2025